Thailand’s political landscape underwent a significant transformation on September 5, 2025, when Anutin Charnvirakul was appointed as Prime Minister, gaining backing from 311 of 492 House Representatives. This moment marked the beginning of a pivotal four-month term, during which Anutin is expected to call for new elections. His arrival in power heralds both opportunities and challenges for the nation’s burgeoning cannabis sector.
The cannabis community in Thailand experienced a mixed bag of emotions after his appointment. Known as the architect of the landmark 2022 cannabis decriminalization, Anutin’s influence could either bolster or complicate the current state of affairs. Following the notable withdrawal of his Bhumjaithai Party from the previous ruling coalition in June, there’s a prevailing consensus that while systematic dismantling might be off the table, the need for serious regulation is apparent. As any seasoned politician might recognize, the current “wild west” landscape demands an approach that prioritizes both medical and therapeutic applications rather than outright prohibition.
Thailand’s Regulatory Cannabis Tightening
This precarious balance between liberalization and control is already reshaping Thailand’s cannabis industry. In June 2025, the Public Health Ministry issued significant regulatory orders aimed at recalibrating the environment. These sweeping measures consist of several notable components:
- Medical Gatekeeping: Only certified medical practitioners can prescribe cannabis flowers to patients with valid prescriptions.
- Licensing Requirements: New permits will be necessary for studying, exporting, selling, or processing cannabis commercially.
- Quality Standards: All cannabis flowers must adhere to the Department for Development of Thai Traditional and Alternative Medicine’s Good Agricultural and Collection Practices (GACP).
- Location Restrictions: Sales are barred in vending machines, online platforms, religious sites, dormitories, parks, zoos, and amusement parks.
- Advertising Prohibition: All forms of cannabis advertising have been banned.
- Reclassification Threat: Officials have raised the possibility of reclassifying cannabis as a schedule 5 narcotic.
This array of regulations presents a complex paradox. Some measures, especially the GACP quality standards, promise to fortify Thailand’s cannabis landscape and boost export capabilities. However, the stringent medical sales requirements threaten to shut down an estimated 12,000 cannabis shops across the country. Small operators and farmers, who were initially meant to benefit from the decriminalization, could bear the brunt of these restrictions. Furthermore, without proper regulatory implementation, the development of Thailand’s cannabis industry hangs in a precarious balance.
The Medicalized Future of Thai Cannabis
Under Anutin’s leadership, the most probable trajectory for cannabis in Thailand seems to veer towards a medicalized model. This would require medical consultations for accessing cannabis, offering genuine advantages for Thai patients. It ensures legitimacy, fosters improved quality standards, and opens avenues for research. However, this approach also obstructs access for individuals lacking relationships with medical professionals.
The intersection with tourism introduces additional complexities. Foreign visitors may find themselves excluded from the revamped system, or regulations might evolve into a more transactional model, perhaps involving a standardized payment system for obtaining prescriptions. Given tourism’s integral role in Thailand’s economy, complete exclusion appears unlikely. Moreover, there are proponents who argue that unregulated cannabis could negatively impact tourism. Thus, a framework that balances both access and regulation is crucial for public and economic interests.
Thailand’s Global Cannabis Market Ambitions
Beyond domestic dynamics, the push for regulation is pivotal for unlocking international prospects. Medical cannabis importers, from Germany to Australia, insist on strict adherence to Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP). These importing nations require rigorous regulatory frameworks that encompass the entire supply chain, from cultivation to export.
For Thailand to solidify its position as Asia’s potential medical cannabis hub, the establishment of credible regulatory frameworks is essential. These frameworks aren’t just about safeguarding local patient access; they’re a gateway to a global market worth billions. Without meeting the stringent requirements, Thai cannabis products risk exclusion from substantial international markets, regardless of their competitive pricing or favorable growing conditions.
If regulators can successfully navigate these challenges, Thai companies might transition from serving domestic walk-in customers to thriving in the export market alongside reputable international competitors.
The Stakes Ahead
The future of Thailand’s cannabis sector hangs in the balance. A failure in regulation, poor implementation, or uneven enforcement could fuel public dissatisfaction, potentially emboldening prohibitionist sentiments in future elections. The cannabis industry stands at a critical crossroads: it risks either establishing itself as a legitimate, regulated entity or sinking into a cautionary tale of rapid liberalization devoid of adequate structural support.
During his fleeting four-month tenure, Anutin is unlikely to serve as either the industry’s destroyer or savior. The success of Thailand’s cannabis future will hinge on striking a delicate equilibrium: fostering regulations that address critics’ fears without stifling opportunities, ensuring medical access for both patients and tourists, and making political decisions that determine cannabis’s role in the nation’s future. The overarching question remains whether Anutin possesses both the political will and the time to champion these essential regulations.
The global cannabis and hemp community is watchfully observant, debating whether Thailand could emerge as a benchmark for regulated medical access in Asia or retreat under political pressure. Significant developments may unfold during Anutin’s brief tenure, but critical milestones are likely to manifest in the elections that follow.
Jason Adelstone will address these dynamics and more at the Asia International Hemp Forum in Bangkok this November, participating in a panel titled “Market Access & Import Requirements for Thai Medical Cannabis: Regulatory Updates Across Key Regions.”